Get the Stockscreener App
41.70
1.14%
0.47
Pre-market:
41.90
0.20
+0.48%
Enliven Therapeutics Inc stock is traded at $41.70, with a volume of 542.20K.
It is up +1.14% in the last 24 hours and up +10.35% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$41.23
Open:
$41.26
24h Volume:
542.20K
Relative Volume:
0.50
Market Cap:
$2.54B
Revenue:
-
Net Income/Loss:
$-103.69M
P/E Ratio:
-22.44
EPS:
-1.8579
Net Cash Flow:
$-70.46M
1W Performance:
-5.76%
1M Performance:
+10.35%
6M Performance:
+78.05%
1Y Performance:
+110.08%
1-Day Range:
$40.06
$43.57
1-Week Range:
$40.06
$46.85
52-Week Range:
$14.79
$48.53
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
41.70 | 2.54B | 0 | -103.69M | -70.46M | -1.8579 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
Enliven Therapeutics (ELVN) price target increased by 11.14% to 52.02 - MSN
Wall Street Zen Downgrades Enliven Therapeutics (NASDAQ:ELVN) to Sell - MarketBeat
Pictet Asset Management Holding SA Sells 94,852 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio - MSN
Director sale notice — Enliven Therapeutics (NASDAQ: ELVN) files Form 144 - Stock Titan
[ARS] Enliven Therapeutics, Inc. SEC Filing - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) seeks larger share authorization - Stock Titan
We're Not Worried About Enliven Therapeutics' (NASDAQ:ELVN) Cash Burn - Sahm
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Enliven Therapeutics CMO Helen Collins sells over $238k in stock By Investing.com - Investing.com South Africa
Enliven Therapeutics CMO Helen Collins sells over $238k in stock - Investing.com Australia
Enliven Therapeutics (ELVN) CMO sells 5,000 shares after option exercise - Stock Titan
Trading the Move, Not the Narrative: (ELVN) Edition - Stock Traders Daily
Enliven Therapeutics (ELVN) Stock: Risk Analysis (Slight Loss) 2026-04-20Top Analyst Buy Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Enliven Therapeutics (ELVN) Stock Investment Grade (Smart Money Active) 2026-04-18Crowd Trend Signals - UBND thành phố Hải Phòng
Enliven Therapeutics Stock Surges 194 Percent Amid CML Market Interest - HarianBasis.co
Enliven Therapeutics stock hits 52-week high at $46.83 By Investing.com - Investing.com India
Enliven Therapeutics (ELVN) soars to 5-year high as analysts 'upbeat' - MSN
Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year HighTime to Buy? - MarketBeat
Enliven Therapeutics stock hits 52-week high at $46.83 - Investing.com
Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market - Insider Monkey
Enliven (ELVN) gets higher price targets from HC Wainwright and Mizuho - MSN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 26.3% in March - MarketBeat
Enliven Therapeutics (NASDAQ: ELVN) asks shareholders to approve charter share increase - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.2%What's Next? - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ELVN Earnings History & Surprises | EPS & Revenue Results | ENLIVEN THERAPEUTICS INC (NASDAQ:ELVN) - ChartMill
(ELVN) Volatility Zones as Tactical Triggers - Stock Traders Daily
ELVN Surges Amid Strategic Acquisition Talks and Analyst Upgrades - StocksToTrade
H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details - Investing.com Canada
Merck’s Acquisition Ups Competition in Pharmaceuticals, Enliven Shines - timothysykes.com
Merck’s Acquisition Sparks Surge in Enliven Therapeutics - StocksToTrade
Enliven Therapeutics Regains Attention as Stock Prices Soar - timothysykes.com
Enliven Therapeutics stock hits 52-week high at $40.66 - Investing.com
Enliven Therapeutics stock hits 52-week high at $40.66 By Investing.com - Investing.com South Africa
Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho - Insider Monkey
Is Enliven Therapeutics (ELVN) Stock a Buy or Sell | Price at $38.94, Up 0.28%Trending Volume Leaders - Cổng thông tin điện tử Tỉnh Sơn La
5 Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Enliven Therapeutics Inc Stock (ELVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Apr 17 '26 |
Option Exercise |
2.48 |
5,000 |
12,400 |
30,000 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Apr 17 '26 |
Sale |
47.67 |
5,000 |
238,352 |
25,000 |
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):